Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
Aevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare Conference
Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
Leaders in genetic science and commercial drug development
Discover the future of novel genetic therapies currently being researched by Aevi Genomic Medicine.
Presentations, information, and news